Semaglutide Injection Dosing Schedule | PlexusDx

Semaglutide injection is administered once per week, with a standard dose escalation protocol beginning at 0.25 mg and reaching therapeutic doses of 1.7–2.4 mg over 16–20 weeks. The once-weekly schedule offers convenience and consistent GLP-1 receptor activation, supported by clinical trials demonstrating sustained weight loss and metabolic improvements.

Understanding semaglutide dosing frequency is essential, but equally important is recognizing that individual response varies significantly. Genetic factors affecting GLP-1 receptor signaling, baseline metabolic biomarkers, and gastrointestinal tolerance all influence how quickly a patient can escalate and which maintenance dose delivers optimal outcomes—making a data-informed conversation with your provider critical.

The Standard Once-Weekly Dosing Schedule Explained

Semaglutide injection follows a fixed once-weekly schedule, typically administered subcutaneously on the same day each week. This consistent frequency maintains steady-state GLP-1 receptor occupancy, reducing appetite signaling and promoting metabolic adaptation over days, not hours—a key difference from daily oral formulations.

The standard titration protocol spans 4 weeks per dose level: 0.25 mg weeks 1–4, 0.5 mg weeks 5–8, 1.0 mg weeks 9–12, 1.7 mg weeks 13–16, and optionally 2.4 mg weeks 17–20. Most patients achieve meaningful weight loss and tolerability at 1.7 mg; 2.4 mg is reserved for those requiring additional efficacy or approved for type 2 diabetes management.

Titration Flexibility: Why Your Dose Timeline May Differ

While the standard protocol progresses every four weeks, clinical practice often deviates based on tolerability, gastrointestinal response, and individual efficacy goals. Some patients require extended time at lower doses; others plateau at 1.0 or 1.7 mg and experience no benefit from escalation. This variability is not failure—it reflects genuine biological differences in how GLP-1 receptors are expressed and function across individuals.

Clinical Response vs. Maximum Dose: What Providers Monitor

The goal of semaglutide therapy is not to reach the highest dose, but to identify the minimum dose producing sustained, tolerable clinical benefit. Clinical trials show that 1.7 mg achieves 15–18% body weight reduction on average; 2.4 mg adds modest incremental benefit (2–4% additional weight loss) at the cost of higher side-effect burden for many patients.

Providers typically assess clinical response at weeks 4–6 of each dose level by evaluating weight trajectory, appetite suppression, blood glucose control (if diabetic), and side-effect severity. If a patient achieves meaningful weight loss and reports satisfied appetite at 1.0 or 1.7 mg, escalation may be deferred or discontinued. This individualized approach is evidence-aligned and reduces unnecessary discomfort.

Safety Considerations and Who Should Adjust Dosing Schedules

Semaglutide is contraindicated in personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2), and requires caution in diabetic retinopathy, acute pancreatitis, or severe renal impairment. Pregnant and nursing individuals should discontinue therapy. Providers must evaluate baseline health status and medication history before initiating and adjusting doses.

Patients experiencing severe nausea, vomiting, dehydration, or persistent GI symptoms should contact their provider before advancing to the next dose. Similarly, those with rapid weight loss (>2 lbs per week) or signs of hypovolemia may benefit from extended titration or medical reassessment. Your healthcare team should guide all dosing decisions in real time, not on a fixed schedule alone.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context regarding predispositions in GLP-1 receptor pathways (GLP1R rs6923761 variant) and metabolic genes (FTO rs9939609, MC4R rs17782313), which can support a more informed conversation with your provider about personalized titration strategy and target maintenance dose. These predispositions may correlate with baseline GLP-1 receptor sensitivity and metabolic response, though they do not predict exact medication response or guarantee outcomes.

The Precision Peptide Genetic Test reveals predispositions in peptide signaling pathways, not pharmacogenomic variants. Understanding your genetic background in GLP-1R, FTO, MC4R, and GIPR (rs1800437) pathways can contextualize why your titration timeline or maintenance dose may differ from standardized protocols. This information should be interpreted with a qualified healthcare provider as one data point among many—baseline biomarkers, prior medication exposure, and clinical response remain equally critical.

When discussing semaglutide dosing with your provider, sharing your genetic predisposition profile alongside baseline metabolic markers (fasting glucose, insulin, weight, BMI) and GI tolerance patterns can facilitate a more personalized titration roadmap. PlexusDx compounded semaglutide is available at flat pricing across all dose levels and commitment tiers, so escalation to higher maintenance doses does not increase your monthly cost—removing financial barriers to finding your optimal therapeutic dose.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Related Reading

• Injection Semaglutide
• Tirzepatide Dosing Schedule Plexusdx
• Semaglutide Providers That Take Fsa Plexusdx
• Semaglutide Injection